Electro-mediated drug administration of mitomycin C in preventing non-muscle-invasive bladder cancer recurrence and progression after transurethral resection of the bladder tumour in intermediate- and high-risk patients

Figures & data

Figure 1. Patients’ disposition

Table 1. Patients’ demographics, clinical characteristics and outcomes

Variable	3 months (n = 101)	6 months (n = 92)
Gender, n (%)  Woman  Man	9 (8.9) 92 (91.1)	8 (8.7) 84 (91.3)
Age, years, median (IQR)	72 (14)	71 (14)
ACCI score, median (IQR)	4 (2)	4 (2)
Previous recurrence, n (%)  No  Yes	57 (56.4) 44 (43.6)	51 (55.4) 41 (44.6)
Previous treatments, n (%)  None  MMC (non-EMDA)  BCG refractory  BCG relapsing	78 (77.2) 14 (13.9) 4 (4.0) 5 (4.9)	70 (76.1) 14 (15.2) 3 (3.3) 5 (5.4)
EORTC risk classification, n (%)  Intermediate risk  High risk	27 (26.7) 74 (73.3)	25 (27.2) 67 (72.8)
EMDA treatment sessions, n (%)  <8 instillations  8 instillations	13 (12.9) 88 (87.1)	12 (13.0) 80 (87.0)
Maintenance sessions, n (%)  None  1–5  ≥6	14 (13.9) 36 (35.6) 51 (50.5)	13 (14.1) 29 (31.5) 50 (54.4)
Treatment response, n (%)  Responder  NMIBC recurrence  NMIBC progression  MIBC progression	86 (85.1) 9 (8.9) 4 (4.0) 2 (2.0)	69 (75.0) 14 (15.2) 4 (4.4) 5 (5.4)

Figure 2. Kaplan–Meier survival estimates at 3 and 6 months

Table 2. Associations between treatment response/progression-free survival and previous BCG failure, number of EMDA/MMC instillations and number of maintenance sessions at 3 and 6 months

	Responder at 3 months (n = 101)		Responder at 6 months (n = 92)			Progression-free survivor at 3 months (n = 101)		Progression-free survivor at 6 months (n = 92)
Variable	No	Yes	No	Yes	OR (95% CI)	No	Yes	No	Yes	OR (95% CI)
Previous BCG failure, n Yes No	5 10	4 82	5 18	3 66	3 months: 0.098 (0.017–0.554)** 6 months: 0.164 (0.024–0.955)*	3 3	6 89	3 6	5 78	3 months: 0.067 (0.008–0.647)** 6 months: 0.128 (0.019–0.942)*
<8 EMDA treatment sessions, n Yes No	6 9	7 79	7 16	5 64	3 months: 0.133 (0.031–0.607)** 6 months: 0.179 (0.040–0.768)**	4 2	9 86	4 5	8 75	3 months: 0.052 (0.004–0.446)** 6 months: 0.133 (0.024–0.841)*
No maintenance sessions, n Yes No	10 5	4 82	11 12	2 67	3 months: 0.024 (0.004–0.128)*** 6 months: 0.033 (0.003–0.185)***	5 1	9 86	5 4	8 75	3 months: 0.021 (0.001–0.232)*** 6 months: 0.085 (0.014–0.506)**

Fisher’s exact test statistical significance: *P < 0.05, **P < 0.01, ***P < 0.001.